Misfortunes do not come in pairs in patients with active moderate-to-severe Graves' orbitopathy

被引：1
|
作者：
Sawicka-Gutaj, Nadia [1 ]
Gruszczynski, Dawid [1 ]
Zawalna, Natalia [1 ]
Nijakowski, Kacper [2 ]
Fichna, Marta [1 ]
Ruchala, Marek [1 ]
机构：
[1] Poznan Univ Med Sci, Dept Endocrinol Metab Disorders & Internal Med, Ul Przybyszewskiego 49, PL-60335 Poznan, Poland
[2] Poznan Univ Med Sci, Dept Conservat Dent & Endodont, Poznan, Poland
来源：
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2024年 / 134卷 / 06期
关键词：
EUROPEAN GROUP; ZNT8;
D O I：
10.20452/pamw.16773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Prevalence of Radiological Signs of Dysthyroid Optic Neuropathy in Magnetic Resonance Imaging in Patients with Active, Moderate-to-Severe, and Very Severe Graves Orbitopathy
    Rutkowska-Hinc, Beata
    Maj, Edyta
    Jablonska, Anna
    Milczarek-Banach, Justyna
    Bednarczuk, Tomasz
    Miskiewicz, Piotr
    EUROPEAN THYROID JOURNAL, 2018, 7 (02) : 88 - 94
  • [22] Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy
    Shen, Liyun
    Ye, Lei
    Zhu, Wei
    Jiao, Qin
    Zhou, Yulin
    Wang, Shu
    Wang, Weiqing
    Ning, Guang
    EUROPEAN THYROID JOURNAL, 2022, 11 (05)
  • [23] Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy
    Wiersinga, Wilmar M.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (02): : 134 - 142
  • [24] Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
    Perez-Moreiras, Jose, V
    Gomez-Reino, Juan J.
    Maneiro, Jose R.
    Perez-Pampin, Eva
    Romo Lopez, Angel
    Rodriguez Alvarez, Fernando M.
    Castillo Laguarta, Jesus M.
    del Estad Cabello, Aurora
    Gessa Sorroche, Maria
    Espana Gregori, Enrique
    Sales-Sanz, Marco
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 195 : 181 - 190
  • [25] RETRACTION: Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy (Retraction of Vol 86, Pg 247, 2017)
    Ye, X.
    Bo, X.
    Hu, X.
    CLINICAL ENDOCRINOLOGY, 2023, 98 (05) : 743 - 743
  • [26] Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?
    Tanda, M. L.
    Piantanida, E.
    Masiello, E.
    Cusini, C.
    Bartalena, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (03) : 351 - 352
  • [27] Efficacy of orbital radiotherapy in moderate-to-severe active graves’ orbitopathy including long-lasting disease: a retrospective analysis
    Jin Hwa Choi
    Jeong Kyu Lee
    Radiation Oncology, 15
  • [28] Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial
    Hoppe, Elena
    Lee, Alan Chun Hong
    Hoppe, David
    Kahaly, George J.
    EUROPEAN THYROID JOURNAL, 2021, 9 (06) : 313 - 320
  • [29] Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy?
    M. L. Tanda
    E. Piantanida
    E. Masiello
    C. Cusini
    L. Bartalena
    Journal of Endocrinological Investigation, 2019, 42 : 351 - 352
  • [30] Efficacy of orbital radiotherapy in moderate-to-severe active graves' orbitopathy including long-lasting disease: a retrospective analysis
    Choi, Jin Hwa
    Lee, Jeong Kyu
    RADIATION ONCOLOGY, 2020, 15 (01)
12345